Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:osimertinib
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2015 |
| gptkbp:ATCCode |
L01EB07
|
| gptkbp:brand |
gptkb:Tagrisso
|
| gptkbp:CASNumber |
1421373-65-0
|
| gptkbp:category |
gptkb:receptor_tyrosine_kinase
antineoplastic agent |
| gptkbp:chemicalFormula |
C28H33N7O2
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD9291
|
| gptkbp:indication |
EGFR T790M mutation-positive NSCLC
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
EGFR inhibitor
|
| gptkbp:molecularWeight |
499.6 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea rash decreased appetite stomatitis |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:162359-55-9
|
| gptkbp:bfsLayer |
6
|